| A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19 A Idris, A Davis, A Supramaniam, D Acharya, G Kelly, Y Tayyar, N West, ... Molecular Therapy 29 (7), 2219-2226, 2021 | 159 | 2021 |
| Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex SM Saayman, DC Lazar, TA Scott, JR Hart, M Takahashi, JC Burnett, ... Molecular therapy 24 (3), 488-498, 2016 | 157 | 2016 |
| Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus B Moyo, K Bloom, T Scott, A Ely, P Arbuthnot Virus research 244, 311-320, 2018 | 81 | 2018 |
| ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells T Scott, B Moyo, S Nicholson, MB Maepa, K Watashi, A Ely, MS Weinberg, ... Scientific reports 7 (1), 7401, 2017 | 69 | 2017 |
| Exosome-mediated stable epigenetic repression of HIV-1 S Shrivastava, RM Ray, L Holguin, L Echavarria, N Grepo, TA Scott, ... Nature communications 12 (1), 5541, 2021 | 68 | 2021 |
| Mesenchymal Stem Cell exosome delivered Zinc Finger Protein activation of cystic fibrosis transmembrane conductance regulator O Villamizar, SA Waters, T Scott, N Grepo, A Jaffe, KV Morris Journal of extracellular vesicles 10 (3), e12053, 2021 | 42 | 2021 |
| AAV-mediated expression of broadly neutralizing and vaccine-like antibodies targeting the HIV-1 envelope V2 region FT van den Berg, NA Makoah, SA Ali, TA Scott, RE Mapengo, ... Molecular Therapy Methods & Clinical Development 14, 100-112, 2019 | 41 | 2019 |
| Improved Cas9 activity by specific modifications of the tracrRNA T Scott, R Urak, C Soemardy, KV Morris Scientific Reports 9 (1), 16104, 2019 | 39 | 2019 |
| Targeted activation of cystic fibrosis transmembrane conductance regulator O Villamizar, SA Waters, T Scott, S Saayman, N Grepo, R Urak, A Davis, ... Molecular Therapy 27 (10), 1737-1748, 2019 | 36 | 2019 |
| Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 TA Scott, A Supramaniam, A Idris, AA Cardoso, S Shrivastava, G Kelly, ... Molecular Therapy Methods & Clinical Development 24, 355-366, 2022 | 34 | 2022 |
| Effect of transcription inhibition and generation of suppressive viral non-coding RNAs DO Pinto, TA Scott, C DeMarino, ML Pleet, TT Vo, M Saifuddin, ... Retrovirology 16, 1-17, 2019 | 26 | 2019 |
| Long non-coding RNA modulation of VEGF-A during hypoxia T Nieminen, TA Scott, FM Lin, Z Chen, S Yla-Herttuala, KV Morris Non-coding RNA 4 (4), 34, 2018 | 15 | 2018 |
| Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine M Guan, L Lim, L Holguin, T Han, V Vyas, R Urak, A Miller, DL Browning, ... Molecular Therapy Methods & Clinical Development 25, 344-359, 2022 | 12 | 2022 |
| Broadly active zinc finger protein-guided transcriptional activation of HIV-1 TA Scott, D O’Meally, NA Grepo, C Soemardy, DC Lazar, Y Zheng, ... Molecular Therapy Methods & Clinical Development 20, 18-29, 2021 | 12 | 2021 |
| Development of a facile approach for generating chemically modified CRISPR/Cas9 RNA T Scott, C Soemardy, KV Morris Molecular therapy Nucleic acids 19, 1176-1185, 2020 | 10 | 2020 |
| Pathogenic Effects of Rift Valley Fever Virus Nss Gene are Alleviated in Cultured Cells by Expressed Antiviral Short Hairpin RNAS T Scott, JT Paweska, P Arbuthnot, MS Weinberg Antiviral therapy 17 (4), 643-656, 2012 | 10 | 2012 |
| Conditionally replicating vectors mobilize chimeric antigen receptors against HIV RZ Urak, C Soemardy, R Ray, S Li, G Shevchenko, T Scott, L Lim, X Wang, ... Molecular Therapy Methods & Clinical Development 19, 285-294, 2020 | 6 | 2020 |
| Prospects and challenges of tissue-derived extracellular vesicles (Ti-EVs) JC Lee, RM Ray, TA Scott Molecular Therapy, 2024 | 5 | 2024 |
| ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep 2017; 7 (1): 7401 T Scott, B Moyo, S Nicholson, M Maepa, K Watashi, A Ely | 5 | |
| Harnessing Rift Valley fever virus NSs gene for cancer gene therapy AM Davis, TA Scott, KV Morris Cancer gene therapy 29 (10), 1477-1486, 2022 | 4 | 2022 |